Patents by Inventor K. Gary J, VANASSE

K. Gary J, VANASSE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF IL-1BETA BINDING ANTIBODIES
    Publication number: 20230088070
    Abstract: Use of an IL-1? binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis, e.g., MDS.
    Type: Application
    Filed: April 25, 2022
    Publication date: March 23, 2023
    Inventors: Andreas BRUEDERLE, Anshu MARATHE, Jean REGARD, Mikael Lee RINNE, Haiying SUN, K. Gary J. VANASSE, Connie WONG
  • COMBINATION OF ANTI TIM-3 ANTIBODY MBG453 AND ANTI TGF-BETA ANTIBODY NIS793, WITH OR WITHOUT DECITABINE OR THE ANTI PD-1 ANTIBODY SPARTALIZUMAB, FOR TREATING MYELOFIBROSIS AND MYELODYSPLASTIC SYNDROME
    Publication number: 20230057071
    Abstract: Combination therapies comprising TIM-3 inhibitors and TGF-? inhibitors are disclosed. The combinations can be used to treat or prevent cancerous conditions and disorders, including myelofibrosis or myelodysplastic syndrome.
    Type: Application
    Filed: December 3, 2020
    Publication date: February 23, 2023
    Inventors: K. Gary J. VANASSE, Haiying SUN, Mirek DOSTALEK, Mikael RINNE, Anshu MARATHE, Luigi MANENTI, Claire FABRE, Fariba KHANSHAN
  • DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN
    Publication number: 20220332821
    Abstract: The present disclosure relates to dosing regimens, formulations, and combinations comprising a multispecific antibody having at least binding specificity towards B cell maturation antigen (BCMA) and a T-cell engaging arm; and methods of using such multispecific antibodies in the treatment or prevention of disease, such as, cancer.
    Type: Application
    Filed: June 22, 2020
    Publication date: October 20, 2022
    Inventors: Kimberly AARDALEN, Aida ABUJOUB, John BLANKENSHIP, Anuradha CONNOR, Mirek DOSTALEK, Tony FLEMING, Brian HOLMBERG, Connie HONG, Lu HUANG, Haihui LU, K. Gary J. VANASSE
  • USE OF AN MDM2 INHIBITOR FOR THE TREATMENT OF MYELOFIBROSIS
    Publication number: 20220331318
    Abstract: The invention relates to the use of an MDM2 inhibitor in the treatment of myelofibrosis (MF). The invention also relates to a pharmaceutical combination comprising a) an MDM2 inhibitor and b) at least one further therapeutic agent, preferably ruxolitinib or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 14, 2020
    Publication date: October 20, 2022
    Inventors: Asa Eliasson, Nelson Guerreiro, Christophe Meille, Hans Menssen, K Gary J Vanasse, Monika Wroclawska
  • USE OF HIGH-AFFINITY, LIGAND-BLOCKING, HUMANIZED ANTI-T-CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN-3 (TIM-3) IGG4 ANTIBODY FOR THE TREATMENT OF MYELOFIBROSIS
    Publication number: 20220306737
    Abstract: The invention relates to the use of an anti-TIM-3 antibody molecule in the treatment of myelofibrosis (MF). The invention also relates to a pharmaceutical combination comprising a) an anti-TIM-3 antibody molecule and b) at least one further therapeutic agent, preferably ruxolitinib or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 14, 2020
    Publication date: September 29, 2022
    Inventors: Asa Eliasson, Hans Menssen, K Gary J Vanasse, Monika Wroclawska
  • COMBINATION THERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPIES
    Publication number: 20210213063
    Abstract: The invention provides a method of treating an adult subject having a hematological cancer, comprising administering to the subject selected dosage regimens comprising a plurality of immune effector cells expressing a CAR molecule in combination with a BTK inhibitor.
    Type: Application
    Filed: May 24, 2019
    Publication date: July 15, 2021
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Randi Isaacs, K. Gary J. Vanasse, Eric Bleickardt, Saar Gill, Marco Ruella, Nathan Amar Singh, Elena Orlando
  • USE OF IL-1BETA BINDING ANTIBODIES
    Publication number: 20200369762
    Abstract: Use of an IL-1? binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis, e.g., MDS.
    Type: Application
    Filed: December 18, 2019
    Publication date: November 26, 2020
    Inventors: Andreas BRUEDERLE, Anshu MARATHE, Jean REGARD, Mikael RINNE, Haiying SUN, K. Gary J. VANASSE, Connie WONG
  • PIM KINASE INHIBITOR COMBINATIONS
    Publication number: 20190290627
    Abstract: The present invention relates to a Pim kinase inhibitor compound that can be used alone or in a pharmaceutical combination. One such combination comprises (a) a JAK inhibitor compound, (b) a Pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.
    Type: Application
    Filed: June 14, 2019
    Publication date: September 26, 2019
    Inventors: Zhu Alexander Cao, Abdel Saci, K. Gary J. Vanasse, Joseph Daniel Growney
  • PIM KINASE INHIBITOR COMBINATIONS
    Publication number: 20170368044
    Abstract: The present invention relates to a Pim kinase inhibitor compound that can be used alone or in a pharmaceutical combination. One such combination comprises (a) a JAK inhibitor compound, (b) a Pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.
    Type: Application
    Filed: September 7, 2017
    Publication date: December 28, 2017
    Applicant: NOVARTIS AG
    Inventors: Zhu Alexander Cao, Abdel Saci, K. Gary J. Vanasse, Joseph Daniel Growney
  • PIM KINASE INHIBITOR COMBINATIONS
    Publication number: 20160175293
    Abstract: The present invention relates to a Pim kinase inhibitor compound that can be used alone or in a pharmaceutical combination. One such combination comprises (a) a JAK inhibitor compound, (b) a Pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.
    Type: Application
    Filed: August 7, 2014
    Publication date: June 23, 2016
    Applicant: NOVARTIS AG
    Inventors: Zhu Alexander CAO, Abdel SACCI, K. Gary J, VANASSE, Joseph GROWNEY